Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Hockey India on Monday announced the 20-member squad for the Men's Junior Asia Cup, a qual
- Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
This medicine may help treat calcium-related disorders Last Updated : 06 Jan 2021 04:28:16 PM IST Researchers have found that a novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.
For the study, published in the journal Biophysical Journal, a team of researchers developed a stabilized form of human calcitonin, which is a peptide drug already used for people with osteoporosis."The technology can help make these calcitonin drugs safer and more effective," said Elizabeth Topp, Professor, Purdue University in the US.The team created a prodrug form of the peptide hormone to increase its effectiveness as an osteoporosis treatment.In humans, calcitonin is the hormone responsible for normal calcium homeostasis. When prescribed to osteoporosis patients, calcitonin inhibits bone resorption, resulting in increased bone mass.Unfortunately, human calcitonin undergoes fibrillation in aqueous solution, leading to reduced efficacy when used as a therapeutic. As a substitute, osteoporosis patients are prescribed salmon calcitonin. It does not fibrillate as rapidly but suffers from low potency and the potential for several adverse side effects."Our approach will increase the therapeutic potential of human calcitonin, promising a more effective option to replace salmon calcitonin for osteoporosis and related disorders," Topp added.To decrease the fibrillation propensity and increase the therapeutic benefit of human calcitonin, Purdue researchers phosphorylated specific amino acid residues."This technology provides a way to stabilize them in a reversible way so that the stabilizing modification comes off when the drug is given to the patient," Topp said.IANS New York For Latest Updates Please-
Join us on
Follow us on
172.31.16.186